ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 57 filers reported holding ADC THERAPEUTICS SA in Q2 2023. The put-call ratio across all filers is 37.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $3,268,120 | -54.7% | 1,675,959 | -10.9% | 0.06% | -57.7% |
| Q4 2022 | $7,219,043 | -20.3% | 1,879,959 | 0.0% | 0.14% | -20.2% |
| Q3 2022 | $9,061,000 | -39.4% | 1,879,959 | 0.0% | 0.18% | -44.4% |
| Q2 2022 | $14,946,000 | -48.5% | 1,879,959 | -4.8% | 0.32% | -29.7% |
| Q1 2022 | $29,013,000 | -27.3% | 1,975,000 | 0.0% | 0.46% | -10.8% |
| Q4 2021 | $39,895,000 | +12.0% | 1,975,000 | +50.5% | 0.51% | +8.5% |
| Q3 2021 | $35,634,000 | +11.5% | 1,311,990 | 0.0% | 0.47% | +9.6% |
| Q2 2021 | $31,948,000 | +43.1% | 1,311,990 | +43.4% | 0.43% | +29.6% |
| Q1 2021 | $22,329,000 | -35.1% | 914,739 | -14.9% | 0.33% | -37.3% |
| Q4 2020 | $34,411,000 | +79.7% | 1,075,000 | +85.2% | 0.53% | +40.8% |
| Q3 2020 | $19,150,000 | +172.8% | 580,483 | +287.0% | 0.38% | +145.1% |
| Q2 2020 | $7,021,000 | – | 150,000 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 11,167,800 | $24,010,770 | 3.60% |
| Sio Capital Management, LLC | 4,020,705 | $8,644,516 | 2.20% |
| Redmile Group, LLC | 14,049,935 | $30,207,360 | 1.16% |
| Vantage Consulting Group Inc | 885,520 | $1,903,868 | 1.10% |
| Blue Owl Capital Holdings LP | 733,568 | $1,577,171 | 0.97% |
| AlphaCentric Advisors LLC | 778,000 | $1,672,700 | 0.93% |
| Affinity Asset Advisors, LLC | 600,000 | $1,290,000 | 0.45% |
| GCM Grosvenor Holdings, LLC | 410,888 | $883,409 | 0.38% |
| Indie Asset Partners, LLC | 93,839 | $201,754 | 0.22% |
| Frazier Life Sciences Management, L.P. | 1,647,030 | $3,541,115 | 0.21% |